Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
A shelf registration statement relating to the shares of common stock and warrants to purchase common stock offered in the public offering described above was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Aptevo’s expectations regarding the closing of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. More information about the risks and uncertainties faced by Aptevo is contained in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering to be filed with the
Source: Aptevo Therapeutics Inc.